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reported in the largest study (N  407; p  0.01). In four studies reporting total 
 gastrointestinal (GI) AE data, donepezil was consistently associated with a lower 
incidence of GI AEs compared to rivastigmine, with three of these reporting a lower 
incidence for donepezil compared to galantamine. In the largest study reporting 
total GI AEs (N  5462), the incidence was donepezil 6%, rivastigmine 14%, and 
galantamine 24%. In all studies, low numbers of CNS and cardiovascular AEs 
were recorded, with similar incidences of events found across the different AChEIs. 
CONCLUSIONS: In routine clinical settings, mild to moderate AD patients who 
received donepezil had fewer total and GI AEs versus patients treated with rivastigmine 
or galantamine.
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OBJECTIVES: Research has shown bipolar patients are at greater risk for somatic 
illnesses than the rest of the population. This study assesses the incidence and relative 
risk (RR) of physical comorbid disease among patients with bipolar disorder. 
METHODS: A large US longitudinal claims database and medical episode grouping 
software was used to construct disease speciﬁc episodes of care for the years 2006–
2007. The case population consisted of individuals 65 years with an episode of bipolar 
disorder and at least 12 months of continuous enrollment (CE). The control population 
were year-, age- and sex-matched individuals with no mental health or substance abuse 
episodes and at least 12 months CE. A total of 102,670 cases and 205,340 controls 
were matched for the year 2006; 109,124 cases and 218,248 controls were matched 
in 2007. Treemaps produced by SAS v. 9.1 are used to convey the relative rankings 
of disease incidence and RR of disease as compared to persons without mental health 
disorders. RESULTS: Compared to controls, cases had elevated RR of disease ranging 
from 1.25 (conditions of the female reproductive system) to 3.14 (trauma or iatrogenic 
conditions). Among the speciﬁc trauma and iatrogenic conditions, poisoning, adverse 
drug reactions and injury the RRs at least 2.5 times higher than controls. Cases had 
a RR of 1.69 for endocrine and metabolic diseases (e.g diabetes, hypothyroidism, 
hypoglycemia). Musculoskeletal conditions and ear, nose and throat conditions were 
the most common types of physical comorbidities among both cases and controls, 
however, RR was 1.59 times higher for cases. CONCLUSIONS: Compared to patients 
with no mental health diagnoses, patients with bipolar disorder are at greater risk 
for a wide range of physical comorbidities. Treemaps are a valuable tool for visualizing 
the relative impact of a broad range of diseases across two populations.
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OBJECTIVES: Although efﬁcacy and safety are 2 key issues to be taken into account 
when choosing an antidepressant, many other factors may also inﬂuence treatment 
initiation. The purpose of the study was to examine the impact of comorbidities on 
the initiation of antidepressants: duloxetine (DLX), valenfaxine (VLX), and escitalo-
pram (ECP) versus other SSRIs (OSSRI) in patients with major depressive disorder 
(MDD). METHODS: A total of 44,026 MDD patients from a large commercial 
administrative claims database were classiﬁed as initiators of DLX (n  7,567), VLX 
(n  6,106), ECP (n  10,239), or OSSRI (n  20,114) during the year 2006. Patients 
were classiﬁed on their ﬁrst index medication during the study period. All patients 
had no active prescription of the same medication(s) in the prior 3 months. On the 
basis of ICD-9-CM, 17 systemic disease classes and 21 individual diseases in the prior 
12 months were identiﬁed. RESULTS: Patients receiving DLX were more likely than 
those receiving VLX, ECP, and OSSRI to be female (75.1% vs. 71.5%, 69.7%, 70.5%, 
p  0.001) and aged 46 years or above (62.3% vs. 54.6%, 49.8%, 50.5%, p  0.001). 
Nearly all systemic disease classes and individual pain diseases were most prevalent 
in DLX patients, followed by VLX and ECP patients, with OSSRI patients being the 
least. Most signiﬁcant predicting comorbid diseases (OR  1.40) of DLX initiation 
versus OSSRI were ﬁbromyalgia (OR  1.86), low back pain (OR  1.54), and bipolar 
disorder (OR  1.43) after adjustment for demographics and other comorbidities. 
However, no comorbid diseases with an OR  1.40 were associated with VLX and 
ECP initiation versus OSSRI. CONCLUSIONS: Patients initiating DLX have the most 
comorbid diseases, followed by VLX, ECP, with patients initiating OSSRI having the 
least. Speciﬁcally, the presence of chronic pain diseases and bipolar disorder appear 
to be most signiﬁcant predictors of DLX initiation relative to OSSRI.
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OBJECTIVES: Conduct a systematic review in schizophrenia relapse prevention, using 
the same methodology as the recent National Institute for Clinical Excellence (NICE) 
Schizophrenia Clinical Guideline. METHODS: Systematic review of CENTRAL, 
EMBASE, MEDLINE, for double-blind RCTs with, amisulpride, aripiprazole, olan-
zapine, paliperidone, quetiapine, risperidone, ziprasidone or zotepine, (completed 
November 2008). Relapse and withdrawal data were extracted using individual trial 
deﬁnitions. Mixed treatment comparison using Markov Chain Monte Carlo simula-
tion was conducted using a random effects model to estimate the risk of relapse, 
treatment discontinuation due to either intolerable adverse effects (DAE) or other 
reasons. Summary effect estimates are presented as Odd Ratios [OR] with 95% Cred-
ible Intervals (95%CrI) calculated versus placebo. RESULTS: Literature searching 
returned 488 papers that identiﬁed 18 RCTs that were of sufﬁcient quality to be 
included in the analysis. Relapse analysis reported quetiapine (XR) followed by ris-
peridone and zotepine as most effective: quetiapine (XR) (OR: 0.151, 95%CrI: 0.021, 
0.52), risperidone (OR: 0.168, 95%CrI: 0.035, 0.52), zotepine (OR: 0.17, 95%CrI: 
0.017, 0.69), olanzapine (OR: 0.225, 95%CrI: 0.081, 0.513), haloperidol (OR: 0.314, 
95%CrI: 0.075, 0.89), ziprasidone (OR: 0.315, 95%CrI: 0.079, 0.85), paliperidone 
(OR: 0.362, 95%CrI: 0.058, 1.214), amisulpride (OR: 0.387, 95%CrI: 0.041, 1.497), 
apriprazole (OR: 0.518, 95%CrI: 0.09, 1.702). Amisulpride, olanzapine and ziprasi-
done reported lowest OR for DAE. Amisulpride, quetiapine (XR) and olanzapine 
reported lowest OR for withdrawal due to other reasons, respectively. The model was 
considered a good ﬁt for relapse and discontinuation due other reasons but not for 
DAE. CONCLUSIONS: When NICE’s schizophrenia guideline was in production, 
quetiapine (XR) was not licensed in the UK and therefore excluded from the health 
economic model. However, it is now available and the above analysis suggests that 
treatment with quetiapine (XR) could potentially provide beneﬁt in the management 
of schizophrenia relapse prevention. No ﬁrm conclusions can be made from the 
 analysis DAE.
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OBJECTIVES: The objective of this analysis was to compare efﬁcacy and safety 
of duloxetine with placebo in the treatment of major depressive disorder in 
Poland. METHODS: Comparison was based on a systematic review, carried out 
according to guidelines published by the Cochrane Collaboration and the Agency 
for Health Technology Assessment in Poland. The most important medical databases 
(MEDLINE, EMBASE, CENTRAL) were searched. Two reviewers independently 
had selected trials, assessed their quality and extracted data. For efﬁcacy analysis 
improvements in Hamilton Rating Scale for Depression (HAM-D) and quality of 
life were measured. Percentage of patients responding to treatment (deﬁned as q50% 
improvement in HAM-D) and percentage of patients achieving total remission 
(deﬁned as a7 points HAM-D-17) were also reported. Head-to-head comparisons 
based on randomized controlled trials (RCTs) were performed both for safety and 
efﬁcacy analysis. RESULTS: The results of 14 RCTs were included in the analysis. 
After 7 to 9 weeks of treatment duloxetine allowed better improvement than 
placebo in HAM-D scores (WMD  2.26 [2.94; 1.57]) and in quality of life (WMD 
 3.60 [4.89; 2.31]). Percentage of patients with response to treatment (RB  1.42 
[1.29; 1.56]), NNT  6.95 [5.53; 9.37]), and with total remission (RB  1.45 [1.29; 
1.64]), NNT  8.92 [6.80; 12.93]) was also statistically signiﬁcantly higher for 
duloxetine group. Although risk of adverse events was signiﬁcantly higher in dulox-
etine treated patients (RR  1.19 [1.13; 1.24]; NNH  8.60 [6.75; 11.84]), no differ-
ences in the incidence of serious adverse events were observed (RR  0.95 [0.49; 1.84]). 
Withdrawals due to adverse events were signiﬁcantly more frequent in duloxetine 
group than in placebo group (RR  2.11 [1.61; 2.77], NNH  17.31 [12.87 26.44]). 
CONCLUSIONS: Duloxetine is efﬁcacious drug in the treatment of patients 
with major depressive disorder. Safety proﬁle seems to be acceptable (slightly worse 
than placebo).
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OBJECTIVES: Update a previously published systematic review1 of pharmacological 
treatments for acute mania in bipolar I disorder, to include recent publications, includ-
ing new formulation quetiapine extended release (XR), and remission rates. 
METHODS: Systematic review of CENTRAL, EMBASE, MEDLINE, for randomised, 
controlled trials comparing placebo to: aripiprazole, carbamazepine, divalproex, halo-
peridol, lithium, olanzapine, quetiapine XR, and risperidone as monotherapy, in 
the treatment of acute mania in bipolar I disorder, published before March 2009. 
Trials of combination therapy and patients non-responsive to previous therapy were 
excluded. Data were combined through random effects meta-analyses using Compre-
hensive Meta Analysis. Summary effect estimates were presented as Relative Risk 
(RR) versus placebo and 95% Conﬁdence Interval (95%CI). RESULTS: 408 publica-
tions were identiﬁed and overall 19 trials from 18 papers were included in the analysis. 
The results for remission reported that risperidone followed by quetiapine XR were 
the most effective antipsychotics: risperidone (RR:1.87, 95%CI:1.22–2.85), quetiap-
ine XR (RR:1.46, 95%CI:1.07–2.01), olanzapine (RR:1.39, 95%CI:1.08–1.79), 
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aripiprazole (RR:1.29, 95%CI:1.05–1.58), haloperidol (RR:1.29, 95%CI:1.03–1.62). 
Lithium followed by divalproex ER were the most effective mood stabilisers: lithium 
(RR:1.73, 95%CI:1.08–2.79), divalproex ER (RR:1.40, 95%CI:1.09–1.80), dival-
proex (1.12, 95%CI:0.81–1.55), carbamazepine ER (not available). The results 
for response reported that risperidone and quetiapine XR were the most effective 
antipsychotics: risperidone (RR:1.77, 95%CI:1.50–2.09), quetiapine XR (RR:1.61, 
95%CI:1.23–2.10), olanzapine (RR:1.54, 95%CI:1.23–1.92), aripiprazole (RR:1.46, 
95%CI:1.26–1.70), haloperidol (RR:1.41, 95%CI:1.19–1.66). Carbamazepine ER 
followed by lithium were the most effective mood stabilisers: carbamazepine ER 
(RR:2.01, 95%CI:1.55–2.61), lithium (RR:1.57, 95%CI:1.28–1.92), divalproex 
(RR:1.46, 95%CI:1.10–1.93), divalproex ER (RR:1.45, 95%CI:1.12–1.87). Due 
to incomplete reporting, the pooled mean difference in YMRS was considered 
unreliable. CONCLUSIONS: Selecting the right pharmacological treatment strategy 
which optimises remission is key to maximising patient outcomes and efﬁcient use of 
health care resources. This analysis suggests that risperidone, quetiapine XR and 
lithium are promising treatment options for bipolar I mania. 1. Smith, Bipolar Disord. 
2007;9:551–560.
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OBJECTIVES: When compared to the general population, people with severe         
mental disorder (SMD) more commonly show obesity, sedentary lifestyles and 
poor dietary choices. This review examines the effectiveness and cost-effectiveness of 
lifestyle interventions on physical activity and dietary choices in people with 
SMD. Included health outcomes were changes in weight, body mass index (BMI) 
and quality of life. METHODS: A systematic E-search strategy was conducted      
using Medline, Web of Science and CINAHL to select articles of lifestyle interventions 
targeting exercise and dietary choices in people with SMD. In addition, the reference 
lists of retrieved articles from the E-databases were hand-searched. RESULTS: 
The search strategy produced 14 randomized and non-randomized comparative trials 
that met the inclusion criteria. Mean duration of the interventions was 20.0 o 10.84 
weeks. Weight loss was reported in 11 studies, with a mean weight change of 1.96 
o 1.84 kg in the intervention groups versus 1.77 o 2.12 kg in the control groups.      
Changes in BMI were 0.87 o 0.69 kg/m² and   0.64 o 0.96 kg/m² respectively in    
intervention and control groups. Differences in changes in weight and BMI between 
intervention and control groups were statistically signiﬁcant in nine studies. The results 
also suggest that quality of life and general health could beneﬁt from these kinds of 
interventions. For example, subjective improvements in quality of life (p  0.047) and 
in overall health (p  0.023) were found in the study of Evans et al. (2005). In 
none of the studies, however, cost-effectiveness was examined. CONCLUSIONS: 
Small weight loss through lifestyle interventions targeting physical activity and 
dietary choices is possible in people with SMD. This is promising given the high 
prevalence of sedentary lifestyles and poor dietary choices and the effects of some 
atypical antipsychotics on weight gain. Further study of both effectiveness and cost-
effectiveness (including the most cost-effective ‘dose’) of lifestyle interventions in 
people with SMD is required.
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OBJECTIVES: To explore differences between age subgroups in QOL in atomoxetine 
treated patients and evaluate correlations between ADHD core symptoms and QOL. 
METHODS: Pooled data of 5 similar clinical atomoxetine trials (8–12 weeks follow-
up, 3 placebo-controlled, 2 open-label) were included in the analysis. All studies used 
the ADHD-RS and the CHIP-CE instruments. Treatment group differences (effect size 
vs. placebo) in CHIP-CE score changes were compared between different age groups 
( /&GE;12YRS);  RESULTS: A total of 611 children (12 yrs) and 183 adolescents 
(q12 yrs) were included. Baseline CHIP-CE total t-scores (mean o SD; norm: 50 o 10) 
were similar in children (29.3 o 11.58) and adolescents (27.5 o 12.29) (p  0.296). 
Greater impairments in the CHIP-CE ‘achievement’ domain were seen in adolescents 
than children (t-scores 31.0 o 10.26 and 28.9 o 10.71, respectively; p  0.05); there 
were no clinically relevant differences in other domains. For the CHIP-CE ‘risk avoid-
ance’ domain, the effect size of atomoxetine was higher in adolescents than in children 
(0.83, p  0.001 and 0.37, p  0.005; age*treatment interaction p  0.059); age group 
differences for other domains and CHIP-CE total scores were not clinically relevant. 
ADHD-RS/CHIP-CE correlations were low at baseline but moderate for change 
from baseline being similar in age groups. Only the ‘risk avoidance’ domain showed 
a trend towards lower correlation of change in adolescents (r  0.384 and r  0.545). 
CONCLUSIONS: Both age groups showed a clinically relevant impairment of QoL 
at baseline which was similar for adolescents and children in four out of ﬁve CHIP-CE 
domains. In both groups, atomoxetine was effective in improving QoL. For the ‘risk 
avoidance’ domain, the effect size of atomoxetine was larger in adolescents than in 
children, while the ADHD-RS/CHIP-CE correlation was lower in adolescents, indicat-
ing a lower association with core symptoms.
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OBJECTIVES: The objective was to compare occurrence of relapse according to 
antipsychotic treatment (monotherapy vs polypharmacy), in a 2 year observational 
cohort of 288 French schizophrenic patients, using different methods of adjustment. 
METHODS: Relapse was deﬁned by a usual, clinically well reproducible and validated 
deﬁnition. The occurrence of relapse between patients receiving one antipsychotic to 
patients receiving more than one antipsychotic was compared according to a Cox 
model including or not the propensity score (PS). The propensity score was calculated 
on socio-economic and demographic information, clinical variables, quality of life, 
medication information and attitude toward treatment. Cox models were built accord-
ing to four usual methods to calculate the propensity score: 1—stepwise PS, continu-
ous, 2—non stepwise PS, continuous, 3—non stepwise PS, quintiles 4—non stepwise 
PS quintiles used to stratify the sample. We also used standard adjustment using all 
variables included in the model estimating the PS. Likelihood, Akaike’s information 
criterion (AIC) criterion and Schwatz’s Bayesian Criterion (SBC) criterion were used 
to compare the models. RESULTS: The standard cox model reports signiﬁcant 
decrease of relapse in patient receiving polytherapy. Consistently the four models 
based on propensity scoring methods did not ﬁnd any difference between the two 
populations. The model that optimizes all criteria (2logL, AIC and SBC) is the model 
using the stratiﬁcation on the propensity score. CONCLUSIONS: Polytherapy is not 
associated to a reduction of relapse while consistently literature reports major risk 
associated to polypharmacy including increased mortality. The use of propensity 
scoring is well established for observational data and this study illustrate that standard 
regression could be misleading.
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OBJECTIVES: To evaluate time to optimization of dose in children with ADHD in 
The Netherlands. METHODS: Claims data from the PHARMO medical record 
linkage system database from 48 geo-demographic areas in The Netherlands (2003–
2006) were analyzed from newly treated ADHD patients aged 6–17 years. Patients 
were followed for at least 12 months after treatment initiation with methylphenidate 
or atomoxetine. Demographic and medication characteristics at treatment initiation, 
and concurrent psychotropic treatments in the year before ADHD treatment initiation 
were recorded. For this analysis, only patients with ³5 dispensings for any ADHD drug 
during follow-up and no missing information on type of drug, strength, and number 
of pills per day were included. Optimized dosing regimen was deﬁned as no change 
in type of drug, strength, and number of pills per day for 5 consecutive dispensings 
(no time restriction between dispensings). Time to optimized dosing regimen was 
deﬁned as the number of days between the ﬁrst dispensing for an ADHD drug (cohort 
entry date) and the ﬁrst of ﬁve unchanged dispensings. RESULTS: Of 4909 children 
initiating treatment from 2003–2006, 3159 met selection criteria. The proportion of 
patients reaching dosing optimization with initial treatment was 69.8% for atomox-
etine (ATX; n  37), 74.8% for short-acting methylphenidate (SA; n  2017), and 
82.4% for long-acting methylphenidate (LA; n  262; P  0.05 for both ATX and SA 
vs LA). The median number of days required to reach optimal dosing regimen was 
49 across the total sample. Among patients achieving dose optimization, those initiat-
ing treatment with LA had a signiﬁcantly shorter time to dose optimization (14 days) 
than patients initially treated with SA (56 days; P  0.001) or ATX (31 days; 
P  0.05). CONCLUSIONS: Time to optimization of dosing regimen in children 
with ADHD in The Netherlands varied according to treatment chosen at initiation 
and was shortest for long-acting methylphenidate. Supported by funding from Shire 
Development Inc.
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OBJECTIVES: Alzheimer’s disease is an irreversible progressive disease that affects 
cognitive, behavioural and functional abilities. The prevalence of Alzheimer’s disease 
is increasing as the world’s population is aging. The primary aim of the study was to 
determine the prescribing patterns and cost of drugs for Alzheimer’s disease in a 
private health care sector patient population. METHODS: A retrospective, exposure-
cohort pharmacoepidemiological study was conducted. Data were obtained from a 
South African private pharmacy group for 2008. The database consisted of 1,578,346 
medicine records. RESULTS: A total of 588 patients (326 females and 262 males) 
received 2623 medicine items for Alzheimer’s disease at a cost of R1,563,701.18 
(average cost per item R596.15). The average age of patients was 75.54 (SD  10.48) 
years, with 78.40% of patients between 70 and 89 years of age. Donepezil was the 
most frequently prescribed active ingredient (37.09%), followed by galantamine 
(36.94%). Donepezil accounted for 39.50% of the cost of Alzheimer medication. No 
notable differences in prescribing patterns were observed over the 12-month period. 
